With so much time and resources being spent addressing daily challenges, sponsors often lack the resources and technology to pursue enterprise-level strategies for planning future clinical trials.In this post, we list some of the key strategic imperatives for biomarker and clinical operations teams, and how can they be addressed by creating wide visibility across vendor and site performance.
The clinical and biomarker operations teams at a mid-sized oncology biotech client depend on QuartzBio’s Sample Intelligence (SI) solution to gain global visibility into their biomarker operations. Using SI, teams can monitor vendor performance within and across studies, an increasingly critical success factor with increased collections and complex sample routing.
Through deep harmonization of data streams using the QuartzBio Platform and Biomarker Intelligence Solution, our client has been able to present historically disconnected assay formats together, in flexible dashboards with visualization and analytical tools – on-study and normalized across studies.
By creating a centralized, harmonized single source of truth, QuartzBio gives translational, operational, data management and information technology teams the power of collaborative, flexible data access, exploration, reporting and collaboration.
For recent protocols, biospecimen collections are designed to be broad and to enable flexible selection from the variety of biomarker assay technologies that are available. Biomarker clinical operations are critical to realizing the potential of biomarker data generation plans. In this post, we explore the relationship between “lab-centric” and “sponsor-centric” sample inventory reporting, and how connecting these inventories can keep data generation on track.
A modern clinical trial, with well-characterized subjects studied over periods of time, presents unmissable opportunities for sponsors to characterize mechanism of action, prioritize target pathways for their pipelines, and generate as much data as possible to support regulatory filings.
Watch on Demand: Integrating Data Silos to Unlock Scientific Insights and Empower Translational Teams Duration: 45 minutes Sign up to watch the webinar on demand: You will learn how to: Abstract of the Webinar Today’s clinical trials have global footprints to reach targeted patient populations and rely on specialty labs running complex assays to assess safety, […]
New York, NY & Bethesda, MD — November 20, 2020 — Precision Medicine Group (PMG) and Blackstone (NYSE: BX) today announced that PMG, a leading next-generation provider of drug development and commercialization services, has completed a major investment and recapitalization led by funds managed by Blackstone (“Blackstone”). The investment includes significant participation from Precision’s co-founders, […]
March 6, 2019 — Bethesda, MD — Precision for Medicine, part of Precision Medicine Group, today announced the acquisition of SimplicityBio, adding artificial intelligence to Precision’s QuartzBio™ multiomic data integration and informatics platform. The addition of an artificial intelligence engine to QuartzBio provides Precision’s clients the most robust, sophisticated end-to-end solution for the “big data” challenge observed in […]
QuartzBio is the only company purpose-built to deliver end-to-end Sample and Biomarker Intelligence for clinical-stage biopharma teams. Powered by a network of domain-specific AI agents, our solutions transform fragmented data into actionable intelligence, enabling conversational insights into your unified ecosystem of sample, clinical, and biomarker data.
QUARTZBIO® is a registered trademark of Precision Regulatory and Translational Sciences, LLC, dba QuartzBio, in the United States and/or other jurisdictions. All rights reserved.
© 2026 QuartzBio.
All rights reserved.
Privacy Notice
Ethics & Third-Party Notice
